

POLICY ON ENTERPRISE RISK MANAGEMENT POLICY

1. Introduction

Cohizon Life Sciences Limited (erstwhile known as "Sajjan India Limited") ("the Company") is committed to effective risk management as a cornerstone of its long-term success. This policy outlines our framework for identifying, assessing, mitigating, and monitoring potential risks across all business operations. Our goal is to enhance stakeholder confidence, support strategic decision-making, and achieve sustainable growth.

2. Purpose

This policy establishes a comprehensive Enterprise Risk Management (ERM) framework to:

- **Create a standardized approach:** Implement a consistent risk management methodology across the organization.
- **Promote continuous improvement:** Continuously evaluate and adapt the ERM framework to address evolving risks and challenges.
- **Define risk assessment procedures:** Establish clear guidelines for identifying, prioritizing, and assessing risks.

3. Risk Management Approach

Our ERM approach follows a structured process:

- **Risk Identification & Assessment:**
 - Proactively identify and assess potential risks using a comprehensive risk assessment methodology.
 - Prioritize risks based on their likelihood of occurrence and potential impact on business objectives.
- **Risk Mitigation:**
 - Develop and implement effective risk mitigation strategies, considering cost-benefit analysis and feasibility.
 - Monitor the effectiveness of mitigation measures and make necessary adjustments.
- **Risk Monitoring & Reporting:**
 - Continuously monitor risks and report findings to relevant stakeholders, including the Board of Directors and senior management.
 - Establish key performance indicators (KPIs) to measure the effectiveness of risk management efforts.

4. Risk Profile

Cohizon Life Sciences Limited identifies and manages a broad spectrum of risks, including:

- **Strategic Risks:** Risks related to long-term objectives, market conditions, and competitive pressures.
- **Operational Risks:** Disruptions in daily business processes, supply chain disruptions, or technology failures.
- **Financial Risks:** Market fluctuations, credit risk, liquidity risk, and currency risk.
- **Environmental Risks:** Climate change, natural disasters, resource depletion, and regulatory compliance.
- **Social Risks:** Labor rights, community relations, supply chain ethics, and reputational risk.
- **Governance Risks:** Corporate governance failures, fraud, corruption, and cybersecurity threats.

5. Risk Management Framework

- **Governance:** The Board of Directors oversees the ERM framework, providing strategic direction and oversight.
- **Risk Management Committee:** A dedicated committee, chaired by the Chief Risk Officer, oversees the implementation and effectiveness of the ERM framework.
- **Risk Management Officer:** The CRO is responsible for leading the ERM function, coordinating risk assessments, and ensuring compliance with the policy.
- **Business Unit Ownership:** Business units are accountable for identifying and managing risks within their respective areas.

6. Key Processes

- **Risk Identification:** Regular risk assessments conducted by business units and centralized risk management teams.
- **Risk Assessment:** Evaluation of risks using quantitative and qualitative methods, considering likelihood and impact.
- **Risk Mitigation:** Development and implementation of strategies to avoid, reduce, transfer, or accept risks.
- **Risk Monitoring:** Continuous monitoring of risks and reporting to relevant stakeholders.
- **Risk Communication:** Effective communication of risk information across the organization.

7. Reporting and Transparency

The Company will report on its risk management activities in its annual reports and sustainability reports, providing key performance indicators and demonstrating transparency.

8. Continuous Improvement

Cohizon Life Sciences Limited is committed to continuously improving its ERM framework. Regular reviews and updates will ensure that the framework remains effective in addressing emerging risks and challenges.

This policy has been approved by the Management and it is adopted and applicable with immediate effect.

A handwritten signature in blue ink, appearing to read "Rajesh Kumar Srivastava", is written over a horizontal line.

Rajesh Kumar Srivastava, MD & CEO

Effective Date:- 16th September 2024 Revision No: 01